Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: A New Drug Shows Promise of Hepatitis C Cure


Los Angeles Times (03.27.13)

Researchers report success in blocking the hepatitis C virus’s ability to colonize liver cells in 18 hepatitis C-infected patients with five weeks of treatment using the antisense oligonucleotide miravirsen. Fourteen weeks after miravirsen injections ended, hepatitis C viral loads were still undetectable in 5 of 18 patients. Miravirsen binds tightly to messenger proteins of liver cells and blocks the hepatitis C virus from colonizing the proteins, which the virus needs to survive and replicate. Without a foothold in liver cells, the hepatitis C virus does not have the chance to develop resistance to protease inhibitors such as teleprevir and boceprivir. As a result, hepatitis C patients could be able to stop taking interferon and ribavirin, which cause side effects like fatigue, anxiety, depression, flu-like symptoms, nausea, and diarrhea. Harvard University physician Dr. Judy Lieberman and Stanford University professor Dr. Peter Sarnow cautioned that long-term miravirsen use could be unsafe because it also targets “genetic material that helps suppress the development of fatty liver, liver fibrosis, and liver tumors”—side effects of hepatitis C. Miravirsen does offer the side benefit of lowering cholesterol; hepatitis C patients taking protease inhibitors cannot take statins that lower cholesterol. Although miravirsen might not present a safe cure for hepatitis C, Sarnow and Lieberman stated that miravirsen could become part of a drug regimen that can keep hepatitis under control. Worldwide, 170 million people are infected with hepatitis C. The full study, “Treatment of HCV Infection by Targeting MicroRNA,” was published online in the New England Journal of Medicine (2013; doi: 10.1056/NEJMoa1209026).


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in March 29, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.